Active Filter(s):
Details:
CTA101, a CRISPR-engineered allogeneic off-the-shelf CD19/CD22 dual-targeted CAR-T cell product, showed manageable safety and promising efficacy in the treatment of r/r B-ALL patients.
Lead Product(s): CTA101
Therapeutic Area: Oncology Product Name: CTA101
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
CTB001 is a fourth-generation autologous CAR-T cell therapy product targeting claudin18.2, which uses Bioheng Explored CAR-T platform technology to enhance the anti-tumor efficacy of the product.
Lead Product(s): CTB001
Therapeutic Area: Oncology Product Name: CTB001
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022
Details:
CTD401 is a universal CAR-T (UCAR-T) cell therapy product developed by Bioheng for the treatment of patients with T-ALL. It has excellent efficacy and superior safety in exploratory clinical studies.
Lead Product(s): CTD401
Therapeutic Area: Oncology Product Name: CTD401
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
The data will be presented regarding the pre-clinical development, manufacturing, and IIT clinical results of the company’s lead product, CTA101, a CRISPR-Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR T cell product, in R/R B-cell acute Lymphoblastic Leukemia.
Lead Product(s): CTA101
Therapeutic Area: Oncology Product Name: CTA101
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020